New Drug For Advanced Basal Cell Carcinoma
It’s the most common form of skin cancer, basal cell carcinoma, and in its advanced stages can become disfiguring and life threatening. For patients with few treatment options, a Mayo Clinic - led study has found that the drug Erivedge (vismodegib) can shrink advanced basal cell carcinoma tumors. The tumors shrank in 43 percent of patients with locally advanced disease and in 30 percent of patients whose disease had spread to other organs.
Lead researcher Aleksandar Sekulic, M.D., Ph.D., a dermatologist and cancer researcher at Mayo Clinic in Arizona says, “This targeted therapy represents a new paradigm in cancer treatment. The findings are very exciting because we haven’t had any therapies before that worked to this degree for advanced basal cell carcinoma.”
Soundbites with Dr. Sekulic are available in the downloads above.
Expert title for broadcast cg:
Dr. Aleksandar Sekulic, Mayo Clinic Dermatologist and Cancer Researcher
Click here for entire news release: DrSekulicNewsRelease2012